CoChat

Hepatic triacylglycerol accumulation and insulin resistance

Open access
Nagle, Cynthia A., Klett, Eric L., Coleman, Rosalind A. · 2009 · Journal of Lipid Research

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

The association of hepatic steatosis with hepatic insulin resistance and type 2 diabetes has prompted investigators to elucidate the underlying mechanism. In this review we focus on pathways of lipid metabolism, and we review recent data, primarily from mouse models, that link lipid intermediates with insulin resistance. Most of the studies that implicate acyl-CoA, lysophosphatidic acid, phosphatidic acid, diacylglycerol, or ceramide rely on indirect associations. Convincing data to support the hypothesis that specific lipid intermediates initiate pathways that alter insulin signaling will require studies in which the concentration of each purported signaling molecule can be manipulated independently.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1194/jlr.r800053-jlr200

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Pathways of FA and triacylglycerol metabolism. FAs used for triacylglycerol (TAG) synthesis or b -oxidation are activated to form acyl-CoAs. If targeted toward b -oxidation, acyl-CoAs are converted to acylcarnitines, enter the mitochondria, and are metabolized by a succession of dehydrogenases that are relatively specific for very-long (VLAD), long (LCAD), medium (MCAD), and short (SCAD) chain acyl-CoAs. The endproduct acetyl-CoA enters the tricarboxylic acid cycle (TCA), producing NADH and FADH, which contribute to ATP formation by oxidative phosphorylation. When excess calories from glucose are available, acetyl-CoA entering the TCA cycle is converted to citrate, which leaves the mitochondria and is used for FA synthesis via acetyl-CoA carboxylase (ACC) and FAS. FA elongases (Elovl) and desaturases (SCD) modify acyl-CoAs, which are used to esterify glycerol-3-phosphate by glycerol-3-P acyltransferases (GPAT). The lysophosphatidic acid (LPA) product is esterified to form phosphatidic acid (PA) by an acyl-glycerol-3-P acyltransferase, the PA is hydrolyzed by phosphatidic acid phosphohydrolase (PAP), and the final esterification step catalyzed by diacylglycerol acyltransferase (DGAT) produces TAG. Liver TAG can be stored in lipid droplets or transferred to VLDL by the mitochondrial TAG transport protein.
Fig. 1 Pathways of FA and triacylglycerol metabolism. FAs used for triacylglycerol (TAG) synthesis or b -oxidation are activated to form acyl-CoAs. If targeted toward b -oxidation, acyl-CoAs are converted to acylcarnitines, enter the mitochondria, and are metabolized by a succession of dehydrogenases that are relatively specific for very-long (VLAD), long (LCAD), medium (MCAD), and short (SCAD) chain acyl-CoAs. The endproduct acetyl-CoA enters the tricarboxylic acid cycle (TCA), producing NADH and FADH, which contribute to ATP formation by oxidative phosphorylation. When excess calories from glucose are available, acetyl-CoA entering the TCA cycle is converted to citrate, which leaves the mitochondria and is used for FA synthesis via acetyl-CoA carboxylase (ACC) and FAS. FA elongases (Elovl) and desaturases (SCD) modify acyl-CoAs, which are used to esterify glycerol-3-phosphate by glycerol-3-P acyltransferases (GPAT). The lysophosphatidic acid (LPA) product is esterified to form phosphatidic acid (PA) by an acyl-glycerol-3-P acyltransferase, the PA is hydrolyzed by phosphatidic acid phosphohydrolase (PAP), and the final esterification step catalyzed by diacylglycerol acyltransferase (DGAT) produces TAG. Liver TAG can be stored in lipid droplets or transferred to VLDL by the mitochondrial TAG transport protein.CC-BY · From the PDF
Fig. 2 Altered insulin signaling by lipid intermediates. Increased nutrient influx raises intracellular FA concentrations. With nutrient surfeit, elevated malonyl-CoA inhibits CPT-1 and b -oxidation and results in increased availability of acyl-CoAs for TAG synthesis and storage or secretion. Intermediates in the TAG biosynthetic pathway activate inhibitors of insulin signaling, including protein kinase C (PKC), mTOR, and S6K, which suppress IRS-1 activation of PIP3. Ceramide inhibits Akt-mediated insulin signaling, derepressing FOXO and leading to increases in transcription of phosphoenolpyruvate (PEPCK) and glucose6-phosphatase (G-6-Pase). These enhance gluconeogenesis and hepatic glucose output. Nutrients act on transcription factors (LXR, ChREBP, SREBP-1c and PPAR g ), which increase transcription of genes involved in FA and TAG synthesis (ACC, FAS, GPAT1). These enhance steatosis and hepatic insulin resistance. DHAP, dihydroxyacetone-P; G3P, glycerol-3-P; GSK, glycogen synthase kinase.
Fig. 2 Altered insulin signaling by lipid intermediates. Increased nutrient influx raises intracellular FA concentrations. With nutrient surfeit, elevated malonyl-CoA inhibits CPT-1 and b -oxidation and results in increased availability of acyl-CoAs for TAG synthesis and storage or secretion. Intermediates in the TAG biosynthetic pathway activate inhibitors of insulin signaling, including protein kinase C (PKC), mTOR, and S6K, which suppress IRS-1 activation of PIP3. Ceramide inhibits Akt-mediated insulin signaling, derepressing FOXO and leading to increases in transcription of phosphoenolpyruvate (PEPCK) and glucose6-phosphatase (G-6-Pase). These enhance gluconeogenesis and hepatic glucose output. Nutrients act on transcription factors (LXR, ChREBP, SREBP-1c and PPAR g ), which increase transcription of genes involved in FA and TAG synthesis (ACC, FAS, GPAT1). These enhance steatosis and hepatic insulin resistance. DHAP, dihydroxyacetone-P; G3P, glycerol-3-P; GSK, glycogen synthase kinase.CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 272

Metadata

Authors
Nagle, C. A., Klett, E. L., & Coleman, R. A.
Affiliations
University of North Carolina at Chapel Hill (US)
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2009-04
Volume
50
Pages
S74-S79
ISSN
0022-2275 (ISSN-L)
OpenAlex
W1972050244
Cited by
272
References
55
Citations by year
2026: 6 · 2025: 10 · 2024: 10 · 2023: 7 · 2022: 13 · 2021: 13 · 2020: 13 · 2019: 13 · 2018: 18 · 2017: 13 · 2016: 27 · 2015: 30 · 2014: 20 · 2013: 30 · 2012: 17
FWCI
1.14
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Lipid Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UNC Libraries
Funders
  • National Institutes of Health (DK56350, DK56598)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK059935, DK 56598, DK 59935, DK56350, P30DK056350)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
Keywords
hepatic insulin resistance, hepatic steatosis, type 2 diabetes, lipid metabolism, acyl-CoA, lysophosphatidic acid, phosphatidic acid, diacylglycerol, ceramide, insulin signaling, lipid intermediates
MeSH terms
Animals, Fatty Liver, Humans, Insulin, Insulin Resistance, Liver, Transcription, Genetic, Triglycerides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hepatic triacylglycerol accumulation and insulin resistance. https://app.cochat.ai/papers/10.1194/jlr.r800053-jlr200
The paper
Nagle, C. A., Klett, E. L., & Coleman, R. A. (2009). Hepatic triacylglycerol accumulation and insulin resistance. Journal of Lipid Research. https://doi.org/10.1194/jlr.r800053-jlr200

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.